Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California. more
Time Frame | CDNA | Sector | S&P500 |
---|---|---|---|
1-Week Return | 52.57% | 1.96% | 1.74% |
1-Month Return | 60.15% | 1.41% | 1.16% |
3-Month Return | 63.51% | -0.06% | 4.18% |
6-Month Return | 100.13% | 14.64% | 18.97% |
1-Year Return | 72.64% | 9.92% | 28.01% |
3-Year Return | -77.75% | 21.12% | 30.32% |
5-Year Return | -54.04% | 76.06% | 96.32% |
10-Year Return | 63.87% | 188.86% | 230.23% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 127.07M | 192.19M | 296.40M | 321.79M | 280.32M | [{"date":"2019-12-31","value":39.49,"profit":true},{"date":"2020-12-31","value":59.73,"profit":true},{"date":"2021-12-31","value":92.11,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":87.11,"profit":true}] |
Cost of Revenue | 45.45M | 63.12M | 97.39M | 112.21M | 104.46M | [{"date":"2019-12-31","value":40.51,"profit":true},{"date":"2020-12-31","value":56.25,"profit":true},{"date":"2021-12-31","value":86.79,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.09,"profit":true}] |
Gross Profit | 81.61M | 129.08M | 199.01M | 209.58M | 175.87M | [{"date":"2019-12-31","value":38.94,"profit":true},{"date":"2020-12-31","value":61.59,"profit":true},{"date":"2021-12-31","value":94.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":83.91,"profit":true}] |
Gross Margin | 64.23% | 67.16% | 67.14% | 65.13% | 62.74% | [{"date":"2019-12-31","value":95.63,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.97,"profit":true},{"date":"2022-12-31","value":96.98,"profit":true},{"date":"2023-12-31","value":93.42,"profit":true}] |
Operating Expenses | 106.14M | 146.79M | 228.73M | 286.81M | 277.77M | [{"date":"2019-12-31","value":37.01,"profit":true},{"date":"2020-12-31","value":51.18,"profit":true},{"date":"2021-12-31","value":79.75,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.85,"profit":true}] |
Operating Income | (24.53M) | (17.71M) | (29.73M) | (77.23M) | (101.90M) | [{"date":"2019-12-31","value":-2453200000,"profit":false},{"date":"2020-12-31","value":-1771500000,"profit":false},{"date":"2021-12-31","value":-2972600000,"profit":false},{"date":"2022-12-31","value":-7723100000,"profit":false},{"date":"2023-12-31","value":-10190000000,"profit":false}] |
Total Non-Operating Income/Expense | 1.57M | (1.76M) | (2.20M) | 4.76M | (76.38M) | [{"date":"2019-12-31","value":32.99,"profit":true},{"date":"2020-12-31","value":-37.07,"profit":false},{"date":"2021-12-31","value":-46.27,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1604.87,"profit":false}] |
Pre-Tax Income | (23.95M) | (19.75M) | (32.09M) | (76.23M) | (190.14M) | [{"date":"2019-12-31","value":-2394700000,"profit":false},{"date":"2020-12-31","value":-1975000000,"profit":false},{"date":"2021-12-31","value":-3208800000,"profit":false},{"date":"2022-12-31","value":-7623400000,"profit":false},{"date":"2023-12-31","value":-19014300000,"profit":false}] |
Income Taxes | (1.98M) | (1.04M) | (1.43M) | 379.00K | 141.00K | [{"date":"2019-12-31","value":-522.16,"profit":false},{"date":"2020-12-31","value":-273.35,"profit":false},{"date":"2021-12-31","value":-376.25,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":37.2,"profit":true}] |
Income After Taxes | (21.97M) | (18.71M) | (30.66M) | (76.61M) | (190.28M) | [{"date":"2019-12-31","value":-2196800000,"profit":false},{"date":"2020-12-31","value":-1871400000,"profit":false},{"date":"2021-12-31","value":-3066200000,"profit":false},{"date":"2022-12-31","value":-7661300000,"profit":false},{"date":"2023-12-31","value":-19028400000,"profit":false}] |
Income From Continuous Operations | (21.97M) | (18.71M) | (30.66M) | (76.61M) | (190.28M) | [{"date":"2019-12-31","value":-2196800000,"profit":false},{"date":"2020-12-31","value":-1871400000,"profit":false},{"date":"2021-12-31","value":-3066200000,"profit":false},{"date":"2022-12-31","value":-7661300000,"profit":false},{"date":"2023-12-31","value":-19028400000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (21.97M) | (18.71M) | (30.66M) | (76.61M) | (190.28M) | [{"date":"2019-12-31","value":-2196800000,"profit":false},{"date":"2020-12-31","value":-1871400000,"profit":false},{"date":"2021-12-31","value":-3066200000,"profit":false},{"date":"2022-12-31","value":-7661300000,"profit":false},{"date":"2023-12-31","value":-19028400000,"profit":false}] |
EPS (Diluted) | (0.08) | 0.08 | 0.29 | (0.39) | (0.64) | [{"date":"2019-12-31","value":-27.59,"profit":false},{"date":"2020-12-31","value":27.59,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-134.48,"profit":false},{"date":"2023-12-31","value":-220.69,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CDNA | |
---|---|
Cash Ratio | 3.02 |
Current Ratio | 4.02 |
Quick Ratio | 3.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CDNA | |
---|---|
ROA (LTM) | -12.88% |
ROE (LTM) | -54.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CDNA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.46 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.54 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.79 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CDNA | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 1.58 |
P/B | 1.69 |
Price/FCF | NM |
EV/R | 0.85 |
EV/Ebitda | NM |
PEG | 0.02 |
CareDx (NASDAQ: CDNA ) just reported results for the first quarter of 2024. CareDx reported earnings per share of -3 cents. This was above the analyst estimate for EPS of -19 cents. The company reported revenue of $72.05 million. This was 13.46% better than the analyst estimate for revenue of $63.50 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.
BRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — CareDx Inc. (CDNA) on Thursday reported a loss of $16.7 million in…
Caredx Inc (CDNA) share price today is $14.83
Yes, Indians can buy shares of Caredx Inc (CDNA) on Vested. To buy Caredx Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CDNA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Caredx Inc (CDNA) via the Vested app. You can start investing in Caredx Inc (CDNA) with a minimum investment of $1.
You can invest in shares of Caredx Inc (CDNA) via Vested in three simple steps:
The 52-week high price of Caredx Inc (CDNA) is $12.93. The 52-week low price of Caredx Inc (CDNA) is $4.8.
The price-to-earnings (P/E) ratio of Caredx Inc (CDNA) is NM
The price-to-book (P/B) ratio of Caredx Inc (CDNA) is 1.69
The dividend yield of Caredx Inc (CDNA) is 0.00%
The market capitalization of Caredx Inc (CDNA) is $767.88M
The stock symbol (or ticker) of Caredx Inc is CDNA